Could a vaccine finally stop the 'Kissing Disease'?

NCT ID NCT05683834

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new vaccine designed to prevent Epstein-Barr virus (EBV) infection, which causes most cases of infectious mononucleosis (mono). Twenty-five healthy adults aged 18 to 25 who had never been infected with EBV received either the vaccine or a placebo. The goal was to see if the vaccine is safe and triggers an immune response that could protect against EBV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EBV gp350-Ferritin vaccine with Matrix-M1 adjuvant
What this could lead to: If successful, this could lead to a vaccine that prevents Epstein-Barr virus infection and the fatigue and complications of mono.
What could go wrong: This is an early-phase trial with only 25 participants, so results may not apply to everyone. The vaccine may not provide strong or lasting protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

herpes simplex infectious disease Herpesviridae infectious disease infectious mononucleosis Epstein-Barr virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPSTEIN-BARR VIRUS INFECTION HERPESVIRUS INFECTIOUS MONONUCLEOSIS

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
University of Minnesota

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.